Cite
HARVARD Citation
Albulescu, M. et al. (n.d.). SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study. Annals of the rheumatic diseases. pp. 867-868. [Online].